Additionally, phosphorylated c-Jun is present in the brains of patients with Alzheimer’s disease [149], and reducing the activity of its phosphorylation enzyme, c-Jun N-terminal kinase, is seen as a potential therapeutic strategy for Alzheimer’s disease [150, 151]. The gene discussed is JUN; the disease is early-onset autosomal dominant Alzheimer disease.